Wall Street Zen upgraded shares of Fulcrum Therapeutics (NASDAQ:FULC – Free Report) from a sell rating to a hold rating in a research report sent to investors on Saturday,Wall Street Zen reports.
Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research report on Thursday, October 15th. One investment analyst has rated the stock with a Buy rating, seven have issued a Hold rating and four have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Fulcrum Therapeutics has a consensus rating of “Reduce” and a consensus target price of $8.20.
View Our Latest Stock Analysis on Fulcrum Therapeutics
Fulcrum Therapeutics Stock Performance
Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.11). As a group, research analysts expect that Fulcrum Therapeutics will post -0.60 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Fulcrum Therapeutics
Institutional investors and hedge funds have recently made changes to their positions in the company. Cetera Investment Advisers acquired a new stake in Fulcrum Therapeutics during the 3rd quarter worth approximately $151,000. FORA Capital LLC bought a new stake in Fulcrum Therapeutics in the 3rd quarter valued at $101,000. Marshall Wace LLP grew its holdings in Fulcrum Therapeutics by 39.4% in the 3rd quarter. Marshall Wace LLP now owns 1,893,289 shares of the company’s stock valued at $7,005,000 after buying an additional 534,866 shares in the last quarter. Empowered Funds LLC acquired a new position in Fulcrum Therapeutics in the 3rd quarter valued at $329,000. Finally, Nantahala Capital Management LLC grew its holdings in Fulcrum Therapeutics by 20.1% in the 3rd quarter. Nantahala Capital Management LLC now owns 6,575,352 shares of the company’s stock valued at $24,329,000 after buying an additional 1,100,312 shares in the last quarter. Institutional investors and hedge funds own 89.83% of the company’s stock.
Fulcrum Therapeutics Company Profile
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts. It develops medicines for genetically defined diseases, with research focused on changing gene expression to address the underlying causes of illness. The company’s work has included programs for sickle cell disease and facioscapulohumeral muscular dystrophy, a rare genetic muscle disorder. Its research has explored approaches such as influencing hemoglobin production and modifying disease-related gene activity.
Further Reading
- Five stocks we like better than Fulcrum Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
